The US myocardial infarction (MI) market is estimated to grow modestly at a CAGR of around 6.4% during the forecast period. The US contributes significantly to the growth of the MI treatment market in North America. The increasing prevalence of heart diseases, high per capita healthcare expenditure and well-developed healthcare infrastructure are the key factors to promote the growth of the myocardial infarction treatment market in the US.